BPAMU
XBI icon

BTG Pactual Asset Management US’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

BTG Pactual Asset Management US’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,000
Closed -$3.46M – 342
2024
Q3 		$3.46M Buy
+35,000
New +$3.44M 0.3% 79

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BTG Pactual Asset Management US's XBI Position: Q1 2026 in Review

BTG Pactual Asset Management US reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.9% in Q1 2026, selling an estimated $17K and leaving 7,146 shares worth $913K. The position accounts for 0.08% of the portfolio, ranked #149.

BTG Pactual Asset Management US first reported a position in XBI in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.31M in Q3 2025. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • BTG Pactual Asset Management US held 7,146 shares of State Street SPDR S&P Biotech ETF worth $913K as of Q1 2026.
  • BTG Pactual Asset Management US sold 136 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $17K.
  • State Street SPDR S&P Biotech ETF made up 0.08% of BTG Pactual Asset Management US's portfolio in Q1 2026, its #149 holding.
  • BTG Pactual Asset Management US first reported a position in State Street SPDR S&P Biotech ETF in Q3 2024 and has held it in 7 quarters since.
  • BTG Pactual Asset Management US's State Street SPDR S&P Biotech ETF position peaked at $1.31M in Q3 2025.
  • 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on BTG Pactual Asset Management US's 13F filing for Q1 2026, filed 14 May 2026.